Concomitant Use of Immunomodulators Affects the Durability of Infliximab Therapy in Children With Crohn's Disease.

[1]  Heather B. Blunt,et al.  Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  A. Griffiths,et al.  Retrospective Cohort Study of Methotrexate Use in the Treatment of Pediatric Crohn's Disease , 2014, Inflammatory bowel diseases.

[3]  A. Griffiths,et al.  Infliximab Maintains Durable Response and Facilitates Catch-up Growth in Luminal Pediatric Crohn's Disease , 2014, Inflammatory bowel diseases.

[4]  M. Dubinsky,et al.  A 10-Year, Single Tertiary Care Center Experience on the Durability of Infliximab in Pediatric Inflammatory Bowel Disease , 2014, Inflammatory bowel diseases.

[5]  A. Cohen,et al.  Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. , 2014, Gastroenterology.

[6]  Stanley B. Cohen,et al.  Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease. , 2014, Gastroenterology.

[7]  M. Dubinsky,et al.  Balancing and Communicating the Risks and Benefits of Biologics in Pediatric Inflammatory Bowel Disease , 2013, Inflammatory bowel diseases.

[8]  A. Griffiths,et al.  Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn’s disease in children: REACH open-label extension , 2011, Current medical research and opinion.

[9]  J. Gisbert,et al.  Long-term Durability of Infliximab Treatment in Crohn's Disease and Efficacy of Dose “Escalation” in Patients Losing Response , 2011, Journal of clinical gastroenterology.

[10]  J. Schweizer,et al.  The duration of effect of infliximab maintenance treatment in paediatric Crohn’s disease is limited , 2011, Alimentary pharmacology & therapeutics.

[11]  P. Rutgeerts,et al.  Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.

[12]  A. Griffiths,et al.  Long‐term outcome of maintenance infliximab therapy in children with Crohn's disease , 2009, Inflammatory bowel diseases.

[13]  K. Van Steen,et al.  Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort , 2008, Gut.

[14]  P. Rutgeerts,et al.  Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. , 2008, Gastroenterology.

[15]  A. Griffiths,et al.  Methotrexate Following Unsuccessful Thiopurine Therapy in Pediatric Crohn's Disease , 2007, The American Journal of Gastroenterology.

[16]  C. Wouters,et al.  A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. , 2007, Arthritis and rheumatism.

[17]  A. Griffiths,et al.  Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. , 2007, Gastroenterology.

[18]  D. Hommes,et al.  Infliximab as first-line therapy in severe pediatric Crohn disease. , 2006, Journal of pediatric gastroenterology and nutrition.

[19]  B. Dijkmans,et al.  Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. , 2005, Arthritis and rheumatism.

[20]  A. Tosteson,et al.  Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[21]  D. Porter,et al.  A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.